O bioma pampa no projeto pedagógico de um curso de licenciatura em ciências da natureza no rio grande do sul

Brazilian ecosystems are a topic that must be present in school curricula. The curriculum is an integral part of formal education, constituting its fundamental function in knowledge systematization, and must be present in basic and higher education. It is essential to analyze the curricula dynamics that constitute the higher education courses for teachers. In consequence, this study investigates an approach of the Pampa Biome, an ecosystem considered neglected, as a possible contextualization and interdisciplinarity strategy for Science Education in the degree course in Natural Sciences at the Federal University of Pampa, Campus Uruguaiana. This is research based on a qualitative case study. The methodology is on the documental analysis of the Pedagogical Project of the respective course, through an analytical matrix composed of questions to which the document must be able to answer. As main results, we found that, despite mentioning the Pampa Biome in the commentaries, the document does not provide a theoretical framework and support that justifies its mentions as thematic in the context in which they are applied. Thus, it is necessary to update the Pedagogical Project and include the Pampa Biome as a contextualization theme for education.Los ecosistemas brasileños son un tema importante, que debe estar presente en los currículos escolares. El currículo es una parte integral de la educación formal, constituyendo su función fundamental en la sistematización del conocimiento lo que exige su presencia en la educación básica y superior. Entendiendo la necesidad de analizar la dinámica de los planes de estudio que conforman los cursos de educación superior para docentes, este estudio se dedicó a investigar el abordaje del Bioma Pampa, un ecosistema considerado descuidado, como posible contextualización y estrategia interdisciplinaria para la Educación Científica en la carrera de Ciencias Naturales de la Universidad Federal de Pampa, Campus Uruguaiana. La investigación se caracteriza por ser un caso de estudio cualitativo, cuyo proceso metodológico se basa en el análisis documental del Proyecto Pedagógico del respectivo curso, a través de una matriz analítica compuesta por preguntas a las que el documento debería dar respuesta. Como principales resultados se encontró que, a pesar de mencionar el Bioma Pampa en los comentarios, el documento no brinda un marco teórico y sustento que justifiquen sus menciones como temáticas en el contexto en el que se aplican. Por ello, es necesario actualizar el Proyecto Pedagógico del Curso e incluir el Bioma Pampa como tema de contextualización para la docencia.Os ecossistemas brasileiros são uma importante temática que deve estar presente nos currículos escolares. O currículo é uma das partes integrantes da educação formal, constituindo sua função fundamental na sistematização dos conhecimentos, devendo estar presentes no ensino básico e superior. Entendendo a necessidade de analisar a dinâmica dos currículos que constituem os cursos superiores formadores de professores, o presente estudo dedicou-se a investigar a abordagem do Bioma Pampa, um ecossistema considerado negligenciado, como uma possível estratégia de contextualização e interdisciplinaridade para o Ensino de Ciências no curso de Licenciatura em Ciências da Natureza da Universidade Federal do Pampa, Campus Uruguaiana. A pesquisa se caracteriza como um estudo de caso, de cunho qualitativo, estando o processo metodológico baseado na análise documental do Projeto Pedagógico do respectivo curso, através de uma matriz analítica composta por perguntas às quais o documento deve ser capaz de responder. Como principais resultados constatou-se que, apesar de mencionar o Bioma Pampa nos ementários, o documento não fornece referencial teórico e aporte que fundamente as suas menções como temática no contexto em que estão aplicadas. Desta forma, faz-se necessária a atualização do Projeto Pedagógico do Curso e a inclusão do Bioma Pampa como temática de contextualização para o ensino

Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A

Niemann-Pick disease type A (NPD-A) is a lysosomal storage disorder characterized by neurodegeneration and early death. It is caused by loss-of-function mutations in the gene encoding for acid sphingomyelinase (ASM), which hydrolyzes sphingomyelin into ceramide. Here, we evaluated the safety of cerebellomedullary (CM) cistern injection of adeno-associated viral vector serotype 9 encoding human ASM (AAV9-hASM) in nonhuman primates (NHP). We also evaluated its therapeutic benefit in a mouse model of the disease (ASM-KO mice). We found that CM injection in NHP resulted in widespread transgene expression within brain and spinal cord cells without signs of toxicity. CM injection in the ASM-KO mouse model resulted in hASM expression in cerebrospinal fluid and in different brain areas without triggering an inflammatory response. In contrast, direct cerebellar injection of AAV9-hASM triggered immune response. We also identified a minimally effective therapeutic dose for CM injection of AAV9-hASM in mice. Two months after administration, the treatment prevented motor and memory impairment, sphingomyelin (SM) accumulation, lysosomal enlargement, and neuronal death in ASM-KO mice. ASM activity was also detected in plasma from AAV9-hASM CM-injected ASM-KO mice, along with reduced SM amount and decreased inflammation in the liver. Our results support CM injection for future AAV9-based clinical trials in NPD-A as well as other lysosomal storage brain disorders.Nation Foundation and by grants from the Spanish Ministry of Economy and Competitivity (SAF-2014-57539-R and SAF2017-87698-R) to M.D.L. and from NIH-NINDS (R01NS073940) to K.S.B. A.P.-C. was a recipient of the FPU predoctoral fellowship from the Spanish Ministry of Economy and Competitivity and Fundación Ramón Areces to the Centro Biología Molecular Severo Ochoa

Chikungunya Virus as Cause of Febrile Illness Outbreak, Chiapas, Mexico, 2014

Since chikungunya virus (CHIKV) was introduced into the Americas in 2013, its geographic distribution has rapidly expanded. Of 119 serum samples collected in 2014 from febrile patients in southern Mexico, 79% were positive for CHIKV or IgM against CHIKV. Sequencing results confirmed CHIKV strains closely related to Caribbean isolates

Amor, empatía y conductas prosociales: una reflexión interdisciplinaria

This book presents, through reflection, the relevance, timeliness and necessity of love, empathy and prosocial behaviors within the framework of the professional and disciplinary work of the authors. The reader will be able to find here what these professionals, academics and intellectuals think and feel about it. Let the reader know that it was not a simple writing project, maybe because of the invitation to think about oneself, maybe because of the presence of the concept of "love" in the academy, or maybe, because we are not so accustomed to putting in the first person the reflection turned from what we relate to day by day. May this text be the excuse to continue to reflect on the role of love, empathy and prosocial behavior in a world that sometimes shows great desolation. May these unknotted reflections allow us to understand and resignify, learn and continue.PublishedEste libro expone, por la vía de la reflexión, la pertinencia, actualidad y necesidad del amor, la empatía y las conductas prosociales en el marco del quehacer profesional y disciplinar de los autores. El lector podrá encontrar aquí lo que esos profesionales, académicos e intelectuales piensan y sienten al respecto. Sepa el lector que no fue un proyecto de escritura sencillo, quizá por la invitación a pensar sobre sí, quizá por la presencia del concepto “amor” en la academia, o quizá, simplemente, porque no estamos tan acostumbrados a poner en primera persona la reflexión devenida de aquello con lo que día a día nos relacionamos. Que sea este texto la excusa para continuar reflexionando sobre el papel del amor, la empatía y las conductas prosociales en un mundo que a veces muestra gran desolación. Que estas reflexiones des-anudadas permitan comprender y resignificar, aprender y continuar

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Información Investigador: Avila Sosa, Edward Ebner

Resumen Curricular Edward Ávila es químico (ULA) y, actualmente, estudiante del Programa de Doctorado en Química, Mención Estudios de Materiales del PIQA-ULA. Fue instructor en la VI Escuela Venezolana para la Enseñanza de la Química. Además, ha trabajado como ayudante de investigación de las líneas de investigación: Efectos del medio en la estructura cristalina de compuestos zwitteriónicos (CDCHT-ULA) y Síntesis, estudio estructural, comportamiento térmico y magnético de algunos complejos del tipo A3B (C2O4)3.H2O (CDCHT-ULA). Y colaborador en de los Profesores Asiloé Mora y Gerzon Delgado. Actualmente, prepara su línea de investigación en el estudio estructural de compuestos con aplicaciones en Biomimética Inorgánica.Universitario40 - 2005Estudio de estructuras moleculares y cristalinas de pro-ligandos nitro-sulfurados con aplicaciones en Bio-mimética Inorgánica.Noviembre de 2005Licenciado en Química+58 274 2401372Facultad de Ciencias.Personal de [email protected]